Rare mixed dementia: A case report

Table 1 Test results of cerebrospinal fluid biomarkers of Alzheimer’s disease

Tested items	Test method	Results		Reference interval
Aβ1-40	ELISA	18412.44 pg/mL	≥ 7000 pg/mL	Positive
			< 7000 pg/mL	Negative
Aβ1-42	ELISA	801.66 pg/mL	≥ 651 pg/mL	Positive
			551-650 pg/mL	Suspicious
			< 550 pg/mL	Negative
t-tau	ELISA	313.44 pg/mL	≤ 399 pg/mL	Negative
			> 399 pg/mL	Positive
p-tau	ELISA	96.48 pg/mL (increase)	≤ 50 pg/mL	Negative
			> 50 pg/mL	Positive
Aβ1-42/Aβ1-40	ELISA	0.04 (decrease)	> 0.05	Negative
			≤ 0.05	Positive

Aβ: Amyloid β-protein; t-tau: Total-micro tubule-associated protein; p-tau: Phosphorylated-micro tubule-associated protein; ELISA: Enzyme-linked immunosorbent assay.

Table 2 Test results of autoimmune encephalitis-related antibodies

Tested items	Sample type	Test method	Detection time	Results
Anti-NMDA antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-LGI1 antibody IgG	CSF	CBA	Pre-treatment	1:100 (positive)
Anti-GABAB antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-CASPR2 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-AMPA1 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-AMPA2 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-IgLON5 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-DPPX antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-GlyR1 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-D2R antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-GAD65 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-mGluR5 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-mGluR1 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-Neurexin-3α antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-KLHL11 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-GABAA antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-AQP4 antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-MOG antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-GFAP antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-ganglionic AChR antibody IgG	CSF	CBA	Pre-treatment	Negative
Anti-LGI1 antibody IgG	Serum	CBA	Pre-treatment	1:100 (positive)
Anti-LGI1 antibody IgG	Serum	CBA	Post-treatment	Negative

CSF: Cerebrospinal fluid; CBA: Cell-based assay; NMDA: N-methyl-D-aspartate; LGI1: Leucine-rich glioma inactivated 1; GABAB: γ-amino butyric acid type B; CASPR2: Contactin associated protein 2; AMPA: α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid; IgLON5: Immunoglobulin-like cell adhesion molecule 5; DPPX: Dipeptidyl‐peptidase‐like protein 6; GlyR1: Glycine receptor 1; D2R: Dopamine 2 receptor; GAD65: Glutamic acid decarboxylase65; mGluR5: Metabotropic glutamate receptor 5; mGluR1: Metabotropic glutamate receptor 1; KLHL11: Kelch-like protein 11; GABAA: γ-amino butyric acidtype A; AQP4: Aquaporin 4; MOG: Myelin oligodendrocyte glycoprotein; GFAP: Glial fibrillary acidic protein; AChR: Acetylcholine receptor.